BREAST CANCER

Radiation therapy may not be the answer in patients with breast cancer over the age of 70, according to Kevin Hughes, MD.

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses recent updates in radiation therapy for breast cancer as discussed in the NCCN guideline.

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival (PFS) for the frontline combination of palbociclib (Ibrance) and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

The breast cancer guidelines in the United States need to be fixed, which can only be accomplished by those on the frontlines. We need oncologists to chime into the discussion.

Following a series of meetings with the FDA, Puma Biotechnology announced that it plans to delay the submission of a new drug application (NDA) until mid-2016 for neratinib.

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD